December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? – Paolo Tarantino
Jul 28, 2023, 08:26

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? – Paolo Tarantino

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support?

Which one should be utilized first? Find the answer in our latest letter to the editor, now published on Annals of Oncology, Giuseppe Curigliano, Sara Tolaney.

Click here for full article.